Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection
miR‐122 is a liver‐specific microRNA, which also circulates in the blood. The levels of miR‐122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR‐122 levels correlate with surrogate markers for viral rep...
Saved in:
| Published in | Journal of viral hepatitis Vol. 19; no. 2; pp. e58 - e65 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.02.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1352-0504 1365-2893 1365-2893 |
| DOI | 10.1111/j.1365-2893.2011.01536.x |
Cover
| Abstract | miR‐122 is a liver‐specific microRNA, which also circulates in the blood. The levels of miR‐122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR‐122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR‐122 levels differ in the different groups of HBV‐infected patients and whether miR‐122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy‐naïve patients with HBV infection (n = 89) and from healthy volunteers (n = 19). The concentration of miR‐122 was assessed by quantitative real‐time reverse‐transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR‐122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (r = 0.259, P < 0.05; r = 0.225, P < 0.05; r = 0.508, P < 0.001, respectively). The miR‐122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (P < 0.001), and inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen could be differentiated by the miR‐122 serum concentration (P < 0.05). As serum miR‐122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR‐122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification. |
|---|---|
| AbstractList | miR‐122 is a liver‐specific microRNA, which also circulates in the blood. The levels of miR‐122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR‐122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR‐122 levels differ in the different groups of HBV‐infected patients and whether miR‐122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy‐naïve patients with HBV infection (
n
= 89) and from healthy volunteers (
n
= 19). The concentration of miR‐122 was assessed by quantitative real‐time reverse‐transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR‐122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (
r
= 0.259,
P
< 0.05;
r
= 0.225,
P
< 0.05;
r
= 0.508,
P
< 0.001, respectively). The miR‐122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (
P
< 0.001), and inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen could be differentiated by the miR‐122 serum concentration (
P
< 0.05). As serum miR‐122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR‐122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification. miR-122 is a liver-specific microRNA, which also circulates in the blood. The levels of miR-122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR-122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR-122 levels differ in the different groups of HBV-infected patients and whether miR-122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy-naïve patients with HBV infection (n = 89) and from healthy volunteers (n = 19). The concentration of miR-122 was assessed by quantitative real-time reverse-transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR-122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (r = 0.259, P < 0.05; r = 0.225, P < 0.05; r = 0.508, P < 0.001, respectively). The miR-122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (P < 0.001), and inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen could be differentiated by the miR-122 serum concentration (P < 0.05). As serum miR-122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR-122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification.miR-122 is a liver-specific microRNA, which also circulates in the blood. The levels of miR-122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR-122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR-122 levels differ in the different groups of HBV-infected patients and whether miR-122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy-naïve patients with HBV infection (n = 89) and from healthy volunteers (n = 19). The concentration of miR-122 was assessed by quantitative real-time reverse-transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR-122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (r = 0.259, P < 0.05; r = 0.225, P < 0.05; r = 0.508, P < 0.001, respectively). The miR-122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (P < 0.001), and inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen could be differentiated by the miR-122 serum concentration (P < 0.05). As serum miR-122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR-122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification. miR-122 is a liver-specific microRNA, which also circulates in the blood. The levels of miR-122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR-122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR-122 levels differ in the different groups of HBV-infected patients and whether miR-122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy-naïve patients with HBV infection (n = 89) and from healthy volunteers (n = 19). The concentration of miR-122 was assessed by quantitative real-time reverse-transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR-122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (r = 0.259, P < 0.05; r = 0.225, P < 0.05; r = 0.508, P < 0.001, respectively). The miR-122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (P < 0.001), and inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen could be differentiated by the miR-122 serum concentration (P < 0.05). As serum miR-122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR-122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification. miR-122 is a liver-specific microRNA, which also circulates in the blood. The levels of miR-122 in serum and plasma correlate with hepatic necroinflammation in patients with hepatitis B virus (HBV) infection. Here, we investigated whether miR-122 levels correlate with surrogate markers for viral replication and translation. Furthermore, we examined whether miR-122 levels differ in the different groups of HBV-infected patients and whether miR-122 levels may be useful to identify patients with higher or lower risk for liver disease progression. Therefore, RNA was extracted from sera of therapy-naive patients with HBV infection (n=89) and from healthy volunteers (n=19). The concentration of miR-122 was assessed by quantitative real-time reverse-transcription PCR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Liver biopsies were examined according to the histological activity index and the degree of fibrosis was assessed. We found that the miR-122 serum concentration correlated with the level of ALT, HBV DNA and HBs antigen (r=0.259, P<0.05; r=0.225, P<0.05; r=0.508, P<0.001, respectively). The miR-122 serum levels discriminated the different patient groups infected with HBV from healthy subjects (P<0.001), and inactive carrier patients with high (>3500IU/mL) or low (<3500IU/mL) levels of HBs antigen could be differentiated by the miR-122 serum concentration (P<0.05). As serum miR-122 levels strongly correlated with HBs antigen, it might be an indicator for viral translation. Furthermore, serum miR-122 levels discriminated HBV carrier patients with high or low risk for disease progression and may, thus, be an additional marker for risk stratification. |
| Author | Piiper, A. Zeuzem, S. Farnik, H. Kronenberger, B. Waidmann, O. Pleli, T. Berger, A. Bihrer, V. |
| Author_xml | – sequence: 1 givenname: O. surname: Waidmann fullname: Waidmann, O. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 2 givenname: V. surname: Bihrer fullname: Bihrer, V. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 3 givenname: T. surname: Pleli fullname: Pleli, T. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 4 givenname: H. surname: Farnik fullname: Farnik, H. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 5 givenname: A. surname: Berger fullname: Berger, A. organization: Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt/Main, Germany – sequence: 6 givenname: S. surname: Zeuzem fullname: Zeuzem, S. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 7 givenname: B. surname: Kronenberger fullname: Kronenberger, B. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie – sequence: 8 givenname: A. surname: Piiper fullname: Piiper, A. organization: Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22239527$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUlvFDEUhC0URBb4C8g3Tt147-4DSMmILCgKUljmaNlum_HQy2C7k8m_p50Jc-BCfPHTc31lqeoYHAzjYAGAGJV4Pu_XJaaCF6RuaEkQxiXCnIpy-wIc7R8O8sxJgThih-A4xjVCmBKOX4FDQghtOKmOgP5qw9TD3psw3t6cFpgQ2Nk720XoB9h652ywQ4I_wzhtIhwd3Kjk502E9z6toFmFcfAGrmzeJx_hGbzzYcq4syb5cXgNXjrVRfvm6T4B388_fVtcFtdfLq4Wp9eFYbQWRWUss23NHNbKVUSJpmlrhLVpVUWco8bVzDLWaN1oYuqK11QjLYhm3AgkOD0B73a-mzD-nmxMsvfR2K5Tgx2nKBuCqoZXnPxfiQXmSLDs-fZJOenetnITfK_Cg_wb4Cyod4I5vxiDdXsJRjJ3JdcyVyJzJTJ3JR-7ktsZ_fgPanxSObEUlO-eY_BhZ3DvO_vw7I_l5x-XeZr5Ysf7mOx2z6vwS4qKVlwuby7kYnm-PGOUy1v6BwPPvC0 |
| CitedBy_id | crossref_primary_10_2174_1566524020666191211153546 crossref_primary_10_18632_oncotarget_21766 crossref_primary_10_18632_oncotarget_23262 crossref_primary_10_1007_s12072_018_9871_0 crossref_primary_10_1007_s00535_024_02135_6 crossref_primary_10_1128_spectrum_04664_22 crossref_primary_10_3748_wjg_v20_i41_15343 crossref_primary_10_4137_BMI_S29512 crossref_primary_10_1002_jmv_24829 crossref_primary_10_1016_j_ejca_2013_06_002 crossref_primary_10_1016_j_trsl_2015_10_010 crossref_primary_10_3389_fphar_2017_00056 crossref_primary_10_1371_journal_pone_0092998 crossref_primary_10_22625_2072_6732_2024_16_1_56_61 crossref_primary_10_3892_etm_2018_7117 crossref_primary_10_1590_0037_8682_0416_2016 crossref_primary_10_1038_s41598_023_50963_y crossref_primary_10_1186_s41544_019_0006_0 crossref_primary_10_1002_ijc_29802 crossref_primary_10_2217_fvl_12_112 crossref_primary_10_1016_j_cyto_2020_155076 crossref_primary_10_3390_v12121440 crossref_primary_10_1093_femspd_ftab050 crossref_primary_10_1016_j_clinbiochem_2015_06_019 crossref_primary_10_1016_S1665_2681_19_31165_2 crossref_primary_10_1517_13543784_2014_867327 crossref_primary_10_3892_mmr_2015_3742 crossref_primary_10_1038_srep33816 crossref_primary_10_1371_journal_pone_0075184 crossref_primary_10_2174_2211536609666201217101414 crossref_primary_10_3390_ijms22189799 crossref_primary_10_3851_IMP2766 crossref_primary_10_3390_biomedicines9080890 crossref_primary_10_3390_cells8121504 crossref_primary_10_4254_wjh_v15_i1_19 crossref_primary_10_1016_j_dld_2018_08_030 crossref_primary_10_1155_2014_435476 crossref_primary_10_1111_1751_2980_12185 crossref_primary_10_1016_j_jceh_2013_09_001 crossref_primary_10_3390_ijms17010078 crossref_primary_10_1111_jvh_12075 crossref_primary_10_1186_s12920_015_0136_7 crossref_primary_10_1007_s10620_015_3649_1 crossref_primary_10_3390_pharmaceutics14071380 crossref_primary_10_1093_infdis_jix140 crossref_primary_10_3389_fgene_2019_00243 crossref_primary_10_1111_liv_12961 crossref_primary_10_1038_ki_2015_333 crossref_primary_10_1155_2021_9957440 crossref_primary_10_1111_jvh_12522 crossref_primary_10_1111_jvh_12001 crossref_primary_10_1097_MD_0000000000002511 crossref_primary_10_1089_aivt_2020_0008 crossref_primary_10_1016_j_ijid_2014_09_020 crossref_primary_10_3390_ijms242417224 crossref_primary_10_1016_j_jhep_2014_10_004 crossref_primary_10_1089_gtmb_2023_0013 crossref_primary_10_1111_jgh_13448 crossref_primary_10_1002_jmv_23540 crossref_primary_10_1371_journal_pone_0255672 crossref_primary_10_1111_jvh_12138 crossref_primary_10_1371_journal_pone_0058236 crossref_primary_10_3390_ijms25020975 crossref_primary_10_3390_biomedicines11051306 crossref_primary_10_1016_j_canlet_2020_02_003 crossref_primary_10_1186_s41544_020_00050_5 crossref_primary_10_1016_j_micpath_2017_10_003 crossref_primary_10_1002_jat_2960 crossref_primary_10_1007_s12072_014_9591_z crossref_primary_10_1371_journal_pone_0080384 crossref_primary_10_1016_j_cca_2015_10_002 crossref_primary_10_1111_jvh_12309 crossref_primary_10_3892_ijo_2019_4870 crossref_primary_10_1007_s12072_021_10277_5 crossref_primary_10_1111_jvh_12944 crossref_primary_10_1007_s40139_014_0049_8 crossref_primary_10_1186_s13148_017_0404_9 crossref_primary_10_1182_blood_2012_07_441360 crossref_primary_10_1371_journal_pone_0136908 crossref_primary_10_4254_wjh_v10_i9_558 crossref_primary_10_3892_or_2015_3924 crossref_primary_10_4236_jbise_2016_910B011 crossref_primary_10_1016_S1499_3872_14_60004_7 crossref_primary_10_3748_wjg_v26_i11_1113 crossref_primary_10_1016_j_virol_2013_10_016 crossref_primary_10_1590_1414_431x20176050 crossref_primary_10_3389_fimmu_2017_00118 crossref_primary_10_3390_bios14090450 crossref_primary_10_1586_egh_12_71 crossref_primary_10_1155_2022_8430276 crossref_primary_10_1556_OH_2012_29387 crossref_primary_10_2217_bmm_12_107 crossref_primary_10_1155_2017_6484835 crossref_primary_10_3390_v5112690 crossref_primary_10_1371_journal_pone_0197637 crossref_primary_10_3748_wjg_v20_i37_13477 crossref_primary_10_1371_journal_pone_0095920 crossref_primary_10_1155_2012_757803 |
| Cites_doi | 10.1016/j.jhep.2008.10.001 10.1016/j.bbrc.2010.07.021 10.1016/0168-8278(95)80226-6 10.3748/wjg.v13.i1.82 10.1056/NEJMra0801644 10.1016/j.bbrc.2008.07.154 10.1373/clinchem.2010.151845 10.1136/gut.2007.123943 10.1016/j.jhep.2010.10.027 10.1016/j.devcel.2006.09.009 10.1074/jbc.M110.107821 10.1002/mc.20712 10.1016/S0960-9822(02)00809-6 10.1126/science.1113329 10.1038/cr.2008.282 10.1373/clinchem.2010.147850 10.1373/clinchem.2009.131797 10.1016/j.jhep.2010.01.014 10.1038/nrc1840 10.1001/jama.295.1.65 10.1001/archinte.166.1.9 10.1053/j.gastro.2010.04.052 10.1038/ajg.2011.161 10.1038/nature02871 10.4161/rna.1.2.1066 |
| ContentType | Journal Article |
| Copyright | 2011 Blackwell Publishing Ltd 2011 Blackwell Publishing Ltd. |
| Copyright_xml | – notice: 2011 Blackwell Publishing Ltd – notice: 2011 Blackwell Publishing Ltd. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TM 7U9 H94 |
| DOI | 10.1111/j.1365-2893.2011.01536.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Nucleic Acids Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Virology and AIDS Abstracts Nucleic Acids Abstracts |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1365-2893 |
| EndPage | e65 |
| ExternalDocumentID | 22239527 10_1111_j_1365_2893_2011_01536_x JVH1536 ark_67375_WNG_CWFWB435_R |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DTERQ DU5 EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT AAHHS ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE WRC WUP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TM 7U9 H94 |
| ID | FETCH-LOGICAL-c4386-7ce4ed84f1baf72a699d801bcda72ff3cf84e449bb9b2c87583b0b62b45c60653 |
| IEDL.DBID | DR2 |
| ISSN | 1352-0504 1365-2893 |
| IngestDate | Fri Jul 11 04:09:46 EDT 2025 Fri Jul 11 16:40:28 EDT 2025 Mon Jul 21 06:03:25 EDT 2025 Tue Jul 01 03:39:40 EDT 2025 Thu Apr 24 23:05:19 EDT 2025 Wed Jan 22 16:27:27 EST 2025 Sun Sep 21 06:31:38 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2011 Blackwell Publishing Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4386-7ce4ed84f1baf72a699d801bcda72ff3cf84e449bb9b2c87583b0b62b45c60653 |
| Notes | ArticleID:JVH1536 istex:ACF364F3C8F00E29469D8BAB4891E0515CA34519 ark:/67375/WNG-CWFWB435-R Equal contribution. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 22239527 |
| PQID | 916150645 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_920795752 proquest_miscellaneous_916150645 pubmed_primary_22239527 crossref_primary_10_1111_j_1365_2893_2011_01536_x crossref_citationtrail_10_1111_j_1365_2893_2011_01536_x wiley_primary_10_1111_j_1365_2893_2011_01536_x_JVH1536 istex_primary_ark_67375_WNG_CWFWB435_R |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-02 February 2012 2012-02-00 2012-Feb 20120201 |
| PublicationDateYYYYMMDD | 2012-02-01 |
| PublicationDate_xml | – month: 02 year: 2012 text: 2012-02 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | Journal of viral hepatitis |
| PublicationTitleAlternate | J Viral Hepat |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242. Laterza OF, Lim L, Garrett-Engele PW et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55: 1977-1983. Brunetto MR, Oliveri F, Colombatto P et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57: 84-91. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375: 315-320. Kosaka N, Iguchi H, Yoshioka Y et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285: 17442-17452. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581. Jaroszewicz J, Calle Serrano B, Wursthorn K et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522. Wong SN, Lok AS. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12. Chang J, Nicolas E, Marks D et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90. Papatheodoridis GV, Hadziyannis E, Tsochatzis E et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008; 57: 500-506. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355. Bihrer V, Friedrich-Rust M, Kronenberger B et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663-1669. Manesis EK, Papatheodoridis GV, Tiniakos DG et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55: 61-68. Xu J, Wu C, Che X et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142. Lagos-Quintana M, Rauhut R, Yalcin A et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739. Qiu L, Fan H, Jin W et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398: 771-777. Zhang Y, Jia Y, Zheng R et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830-1838. Chen CJ, Yang HI, Su J et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269. 2010; 56 2006; 11 2008; 18 2002; 12 2006; 295 2011; 55 2006; 6 2010; 285 2008; 57 2011; 57 2004; 1 2007; 13 2004; 431 2009; 55 2011; 106 2009; 50 2010; 139 2010; 398 1995; 22 2011; 50 2008; 359 2005; 309 2008; 375 2010; 52 2006; 166 e_1_2_9_10_2 e_1_2_9_12_2 e_1_2_9_11_2 e_1_2_9_14_2 e_1_2_9_13_2 e_1_2_9_16_2 e_1_2_9_15_2 e_1_2_9_18_2 e_1_2_9_17_2 e_1_2_9_19_2 e_1_2_9_21_2 e_1_2_9_20_2 e_1_2_9_23_2 e_1_2_9_22_2 e_1_2_9_7_2 e_1_2_9_6_2 e_1_2_9_5_2 e_1_2_9_4_2 e_1_2_9_3_2 e_1_2_9_2_2 e_1_2_9_9_2 e_1_2_9_8_2 e_1_2_9_25_2 e_1_2_9_24_2 e_1_2_9_26_2 |
| References_xml | – reference: Qiu L, Fan H, Jin W et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398: 771-777. – reference: Chen CJ, Yang HI, Su J et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. – reference: Manesis EK, Papatheodoridis GV, Tiniakos DG et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55: 61-68. – reference: Brunetto MR, Oliveri F, Colombatto P et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490. – reference: Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90. – reference: Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375: 315-320. – reference: European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242. – reference: Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355. – reference: Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450. – reference: Lagos-Quintana M, Rauhut R, Yalcin A et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739. – reference: Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006. – reference: Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269. – reference: Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57: 84-91. – reference: Wong SN, Lok AS. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12. – reference: Xu J, Wu C, Che X et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142. – reference: Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699. – reference: Zhang Y, Jia Y, Zheng R et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830-1838. – reference: Jaroszewicz J, Calle Serrano B, Wursthorn K et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522. – reference: Papatheodoridis GV, Hadziyannis E, Tsochatzis E et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008; 57: 500-506. – reference: Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500. – reference: Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581. – reference: Bihrer V, Friedrich-Rust M, Kronenberger B et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663-1669. – reference: Laterza OF, Lim L, Garrett-Engele PW et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55: 1977-1983. – reference: Kosaka N, Iguchi H, Yoshioka Y et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285: 17442-17452. – reference: Chang J, Nicolas E, Marks D et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113. – volume: 12 start-page: 735 year: 2002 end-page: 739 article-title: Identification of tissue‐specific microRNAs from mouse publication-title: Curr Biol – volume: 285 start-page: 17442 year: 2010 end-page: 17452 article-title: Secretory mechanisms and intercellular transfer of microRNAs in living cells publication-title: J Biol Chem – volume: 55 start-page: 1977 year: 2009 end-page: 1983 article-title: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury publication-title: Clin Chem – volume: 431 start-page: 350 year: 2004 end-page: 355 article-title: The functions of animal microRNAs publication-title: Nature – volume: 18 start-page: 997 year: 2008 end-page: 1006 article-title: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases publication-title: Cell Res – volume: 1 start-page: 106 year: 2004 end-page: 113 article-title: miR‐122, a mammalian liver‐specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT‐1 publication-title: RNA Biol – volume: 50 start-page: 227 year: 2009 end-page: 242 article-title: EASL Clinical Practice Guidelines: management of chronic hepatitis B publication-title: J Hepatol – volume: 6 start-page: 259 year: 2006 end-page: 269 article-title: Oncomirs – microRNAs with a role in cancer publication-title: Nat Rev Cancer – volume: 22 start-page: 696 year: 1995 end-page: 699 article-title: Histological grading and staging of chronic hepatitis publication-title: J Hepatol – volume: 359 start-page: 1486 year: 2008 end-page: 1500 article-title: Hepatitis B virus infection publication-title: N Engl J Med – volume: 57 start-page: 84 year: 2011 end-page: 91 article-title: Direct serum assay for microRNA‐21 concentrations in early and advanced breast cancer publication-title: Clin Chem – volume: 56 start-page: 1830 year: 2010 end-page: 1838 article-title: Plasma microRNA‐122 as a biomarker for viral‐, alcohol‐, and chemical‐related hepatic diseases publication-title: Clin Chem – volume: 398 start-page: 771 year: 2010 end-page: 777 article-title: miR‐122‐induced down‐regulation of HO‐1 negatively affects miR‐122‐mediated suppression of HBV publication-title: Biochem Biophys Res Commun – volume: 106 start-page: 1663 year: 2011 end-page: 1669 article-title: Serum miR‐122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection publication-title: Am J Gastroenterol – volume: 57 start-page: 500 year: 2008 end-page: 506 article-title: Serum apoptotic caspase activity as a marker of severity in HBeAg‐negative chronic hepatitis B virus infection publication-title: Gut – volume: 52 start-page: 514 year: 2010 end-page: 522 article-title: Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)‐infection: a European perspective publication-title: J Hepatol – volume: 13 start-page: 82 year: 2007 end-page: 90 article-title: Pathogenesis of hepatitis B virus infection publication-title: World J Gastroenterol – volume: 55 start-page: 61 year: 2011 end-page: 68 article-title: Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg‐negative chronic hepatitis B publication-title: J Hepatol – volume: 295 start-page: 65 year: 2006 end-page: 73 article-title: REVEAL‐HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level publication-title: JAMA – volume: 375 start-page: 315 year: 2008 end-page: 320 article-title: miR‐122 targets an anti‐apoptotic gene, Bcl‐w, in human hepatocellular carcinoma cell lines publication-title: Biochem Biophys Res Commun – volume: 139 start-page: 483 year: 2010 end-page: 490 article-title: Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers publication-title: Gastroenterology – volume: 309 start-page: 1577 year: 2005 end-page: 1581 article-title: Modulation of hepatitis C virus RNA abundance by a liver‐specific MicroRNA publication-title: Science – volume: 50 start-page: 136 year: 2011 end-page: 142 article-title: Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis publication-title: Mol Carcinog – volume: 166 start-page: 9 year: 2006 end-page: 12 article-title: Treatment of hepatitis B: who, when, and how? publication-title: Arch Intern Med – volume: 11 start-page: 441 year: 2006 end-page: 450 article-title: The diverse functions of microRNAs in animal development and disease publication-title: Dev Cell – ident: e_1_2_9_5_2 doi: 10.1016/j.jhep.2008.10.001 – ident: e_1_2_9_16_2 doi: 10.1016/j.bbrc.2010.07.021 – ident: e_1_2_9_20_2 doi: 10.1016/0168-8278(95)80226-6 – ident: e_1_2_9_23_2 doi: 10.3748/wjg.v13.i1.82 – ident: e_1_2_9_2_2 doi: 10.1056/NEJMra0801644 – ident: e_1_2_9_26_2 doi: 10.1016/j.bbrc.2008.07.154 – ident: e_1_2_9_21_2 doi: 10.1373/clinchem.2010.151845 – ident: e_1_2_9_22_2 doi: 10.1136/gut.2007.123943 – ident: e_1_2_9_4_2 doi: 10.1016/j.jhep.2010.10.027 – ident: e_1_2_9_11_2 doi: 10.1016/j.devcel.2006.09.009 – ident: e_1_2_9_13_2 doi: 10.1074/jbc.M110.107821 – ident: e_1_2_9_18_2 doi: 10.1002/mc.20712 – ident: e_1_2_9_14_2 doi: 10.1016/S0960-9822(02)00809-6 – ident: e_1_2_9_25_2 doi: 10.1126/science.1113329 – ident: e_1_2_9_12_2 doi: 10.1038/cr.2008.282 – ident: e_1_2_9_17_2 doi: 10.1373/clinchem.2010.147850 – ident: e_1_2_9_24_2 doi: 10.1373/clinchem.2009.131797 – ident: e_1_2_9_7_2 doi: 10.1016/j.jhep.2010.01.014 – ident: e_1_2_9_10_2 doi: 10.1038/nrc1840 – ident: e_1_2_9_3_2 doi: 10.1001/jama.295.1.65 – ident: e_1_2_9_8_2 doi: 10.1001/archinte.166.1.9 – ident: e_1_2_9_6_2 doi: 10.1053/j.gastro.2010.04.052 – ident: e_1_2_9_19_2 doi: 10.1038/ajg.2011.161 – ident: e_1_2_9_9_2 doi: 10.1038/nature02871 – ident: e_1_2_9_15_2 doi: 10.4161/rna.1.2.1066 |
| SSID | ssj0013251 |
| Score | 2.3584173 |
| Snippet | miR‐122 is a liver‐specific microRNA, which also circulates in the blood. The levels of miR‐122 in serum and plasma correlate with hepatic necroinflammation in... miR-122 is a liver-specific microRNA, which also circulates in the blood. The levels of miR-122 in serum and plasma correlate with hepatic necroinflammation in... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e58 |
| SubjectTerms | Adult Biomarkers - blood Biopsy DNA, Viral - blood Female HBs antigen HBV carrier HBV DNA hepatitis B Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - isolation & purification Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - pathology Hepatitis B, Chronic - physiopathology Histocytochemistry Humans Liver - pathology Male microRNA-122 MicroRNAs - blood Middle Aged Prognosis Real-Time Polymerase Chain Reaction Retrospective Studies Serum - chemistry |
| Title | Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection |
| URI | https://api.istex.fr/ark:/67375/WNG-CWFWB435-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2893.2011.01536.x https://www.ncbi.nlm.nih.gov/pubmed/22239527 https://www.proquest.com/docview/916150645 https://www.proquest.com/docview/920795752 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFH5Cm0BcNhgwwi_5gLilah07jo_boFST1kPF6G6W7Tii6paiJpkGJ_6E_Y37S_CL02pFE5oQt8jJS-KX9-LP9ufPAO-tHHCdFzp2CcdpRqNjzXIbC5kVOpHGYxBcO3wyTken7PiMn3X8J1wLE_Qh1gNumBnt_xoTXJtqM8lbhpZvcDslTp-8aQ_xpD-BMvofJ_TWhAIPfS9O4z7vs01Sz5032mipttHpV3fB0E1U2zZLw12YryoU2CjzXlObnv35h9bj_6nxE9jp0Cs5COH2FB64cg8ehv0sf-zBo5Nupv4Z5P4n1FyQC-T7TcYHN7-uB5SSc6QoVWRWktXGLDVp15VUZFGQTuO1Ijg4TGyQ7SXfHJbXs4ocksvZskHzQCArn8Pp8NOXo1Hc7egQW5ZkaSysYy7PWOFjohBUp1Lmvok0NteCFkVii4w5xqQx0lDru1JZYvompYZxm6KK7gvYKhelewnEJtJDR6bpwGmWaSdzay23MjGMCs1MBGL19ZTt5M5x141zdavb492p0J0K3alad6qrCAZry-9B8uMeNh_aAFkb6OUcKXOCq-n4szqaDqeHHpiqSQRkFUHKJzLOzujSLZpKScTeqB74l0toX0iPr2kE-yH41s9DmOcdIiJI2xC695ur468jPHr1r4av4bEvpoHJ_ga26mXj3nqgVpt3bQr-Bm1MLcg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwED-hTcBe-DNgC3_9gHhL1Tp2Ej9uE6WMtQ_VRvdm2Y4jqnXp1CRo2xMfgc_IJ8EXp9WKJjQh3qLIl8SXO_tn3_l3AO-N6HGV5Sq0Eccwo1ahYpkJE5HmKhLaYRA8OzwcxYMTdnjKT9tyQHgWxvNDrDbc0DOa8RodHDek1728SdFyM25Lxem8N-44QLnZhOsQIY3pjZAC96svTsMu77L1tJ5bn7Q2V22i2i9vA6LruLaZmPqPYbbsks9HOevUle6Y6z_YHv9Tn5_AoxbAkj1vcU_hni224b4vaXm1DQ-GbbD-GWRuHKrPyTmm_I1He79-_OxRSmaYpVSSaUGWtVkq0hwtKck8Jy3Na0lwf5gYz9xLvlm8X01Lsk--Txc1ivscsuI5nPQ_Hh8MwraoQ2hYlMZhYiyzWcpyZxZ5QlUsROZmSW0yldA8j0yeMsuY0FpoatxqKo10V8dUM25iJNJ9ARvFvLC7QEwkHHpkivasYqmyIjPGcCMizWiimA4gWf4-aVrGcyy8MZM3Vj5OnRLVKVGdslGnvAygt5K88Kwfd5D50FjISkAtzjBrLuFyMvokDyb9yb7DpnIcAFmakHS-jAEaVdh5XUqB8BsJBP_ShHYT4SA2DWDHW9_qfYj0nEKSAOLGhu785fLw6wCvXv6r4Dt4ODgeHsmjz6Mvr2DLNaE-sf01bFSL2r5xuK3Sbxt__A1VbzHm |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1db9MwFL1Cm5h4YWPACIzhB8RbqtZx4vhxG3RlsApVjO7Nsh1HVN3SqUmmwRM_gd_IL8E3TqsVTWhCvEWRbz5u7vU9jo-PAV4b0YtVlqvQRjFOM2oVKpaZkIs0V5HQDoPg2uGTYTI4Zcdn8VnLf8K1MF4fYvnDDTOj6a8xwS-zfDXJG4aWK7itEqdL3qTj8OQ6S1zVRIA0ojdmFGI_-Ipp2I27bJXVc-uVVkrVOnr9-jYcugprm7rU34Tp4o08HWXaqSvdMd__EHv8P6-8BQ9b-Er2fbw9gnu22Ib7fkPLb9uwcdJO1T-GzPVC9QW5QMLfaLj_68fPHqXkHDlKJZkUZLEzS0WahSUlmeWkFXktCf4dJsbr9pKvFs9Xk5IckKvJvEZzzyArnsBp_93nw0HYbukQGhalSciNZTZLWe6CIudUJUJkrkZqkylO8zwyecosY0JroalxY6k00l2dUM1ik6CM7lNYK2aFfQbERMJhR6ZozyqWKisyY0xsRKQZ5YrpAPji60nT6p3jthvn8sa4x7lTojslulM27pTXAfSWlpde8-MONm-aAFkaqPkUOXM8luPhkTwc98cHDpnKUQBkEUHSZTJOz6jCzupSCgTfKB_4lya0y4UD2DSAHR98y_shznMO4QEkTQjd-cnl8ZcBHj3_V8NXsPHpbV9-fD_88AIeuBbUs9p3Ya2a1_alA22V3muy8TeCfzCV |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+microRNA-122+levels+in+different+groups+of+patients+with+chronic+hepatitis+B+virus+infection&rft.jtitle=Journal+of+viral+hepatitis&rft.au=Waidmann%2C+O.&rft.au=Bihrer%2C+V.&rft.au=Pleli%2C+T.&rft.au=Farnik%2C+H.&rft.date=2012-02-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1352-0504&rft.eissn=1365-2893&rft.volume=19&rft.issue=2&rft.spage=e58&rft.epage=e65&rft_id=info:doi/10.1111%2Fj.1365-2893.2011.01536.x&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_CWFWB435_R |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-0504&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-0504&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-0504&client=summon |